SCHEMBL48702

SCHEMBL48702

Cc1nc(NC(=O)Cc2cccnc2)sc1-c1ccc(S(C)(=O)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 5/20 0.61
PIK3CD O00329 4/20 0.61
PIK3CA P42336 4/20 0.61
PIK3CB P42338 3/20 0.61
PI4KB Q9UBF8 10/20 0.58
WNT3A P56704 1/20 0.50
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 1/20 0.49
RORC P51449 1/20 0.48
GLS O94925 1/20 0.47
NAMPT P43490 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48700 0.88 PIK3CD (0.66) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL27597047 0.77 PIK3CA (0.81) PIK3CGPIK3CDPIK3CAPIK3CBMEN1
SCHEMBL48857 0.77 PIK3CG (1.00) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL48623 0.74 PIK3CD (0.72) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL7843818 0.74 RORC (0.68) PI4KBMEN1ALDH1A1KMT2AHSD17B10
SCHEMBL7846410 0.74 RORC (0.68) PI4KBMEN1ALDH1A1KMT2AHSD17B10
SCHEMBL1784577 0.72 PIK3CD (0.69) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL48850 0.72 PIK3CD (0.69) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL17881206 0.72 PIK3CD (0.51) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL48661 0.72 PIK3CD (0.53) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP claimed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
CN-100548996-C 5-phenylthiazole derivatives and their use for the preparation of medicaments NOVARTIS AG (CH) 2009-10-14 CN disclosed
CN-1639139-A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2005-07-13 CN disclosed
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors NOVARTIS AG (CH) 2005-06-02 US disclosed
EP-1480962-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS Novartis AG (CH) 2004-12-01 EP disclosed
WO-2003072557-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B PIK3CG 8/4885PIK3CD 4/4885PIK3CA 1/4885
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors PIK3CA, PIK3R5, PIP5K1B PIK3CG 8/4885PIK3CD 4/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.